Advertisement
News
Advertisement

Helix Therapeutics handed $2.5M in new funding

Tue, 11/23/2010 - 6:33am
Mass High Tech: The Journal of New England Technology

Helix Therapeutics LLC, a New Haven, Conn.-based biopharmaceutical company, has landed $2.5 million in new funding from venture firm Canaan Partners and the quasi-public state funding entity Connecticut Innovations.

According to Helix officials, the new funds will be used to move forward its proprietary targeted gene modification (TGM) technology platform, which the company says can correct certain genetic mutations in blood stem cells of patients with rare genetic diseases such as sickle cell anemia, B-Thalassemia and lysosomal storage disorders.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading